-
Subject Areas on Research
-
A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury.
-
Amyotrophic lateral sclerosis: current practice and future treatments.
-
Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine.
-
Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.
-
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
-
Efficacy of Glutamate Modulators in Tic Suppression: A Double-Blind, Randomized Control Trial of D-serine and Riluzole in Tourette Syndrome.
-
Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold.
-
Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent.
-
Pharmacology of riluzole in acute spinal cord injury.
-
Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.
-
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
-
The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1.